Home  >  News
Eppen_CellXpert_Feb25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
Corporate + Font Resize -

US FDA completes pre-approval inspection of Lupin’s edaravone oral suspension facility in Somerset with no observations

Our Bureau, Mumbai
Monday, February 3, 2025, 14:45 Hrs  [IST]

Global pharma major Lupin Limited (Lupin) announced that the United States Food and Drug Administration (FDA) has completed a pre-approval inspection (PAI) of edaravone oral suspension, 105 mg/ 5 mL at its manufacturing facility in Somerset, New Jersey. The inspection was carried out from January 28 to February 1, 2025, and concluded with zero 483 observations.
 
Nilesh Gupta, managing director, Lupin said, “The successful outcome of the US FDA inspection at our Somerset facility is a testament to our commitment to uphold and maintain the highest standards of quality, compliance and safety across our facilities. We remain steadfast in our mission to improve the lives of our patients globally.”
 
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Avians_2025
chemexpoindia
ana-Lab-India_25
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram